Cat. No.: HY-N2421

Sequoyitol

(Synonyms: 5-O-Methyl-myo-inositol)

1 Cited Publications

Avis client

Based on 1 publication(s) in Google Scholar

Sequoyitol (5-O-Methyl-myo-inositol) is an orally active hypoglycemic agent and antioxidant. Sequoyitol can be isolated from herbaceous plants. Sequoyitol downregulates the expression of NF-κB and TGF-β1, reduces ROS production and malondialdehyde levels, and enhances total antioxidant capacity. Sequoyitol activates the insulin signaling pathway, including the phosphorylation of IR, IRS1 and Akt. Sequoyitol increases serum insulin levels, inhibits hepatic glucose production, and promotes cellular glucose uptake. Sequoyitol antagonizes TNFα-induced inhibition of the insulin signaling pathway, and decreases blood urea nitrogen and serum creatinine levels. Sequoyitol elicits potential peaks in the chemosensors of adult and larval Atrophaneura alcinous, and acts as an oviposition stimulant for female Atrophaneura alcinous. Sequoyitol can be used in research related to type 2 diabetes, insulin resistance, hyperglycemia, impaired glucose tolerance and diabetic nephropathy.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 98.0%
CAS No.: 523-92-2
Formule: C₇H₁₄O₆
Masse moléculaire:194.18

Stockage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Sequoyitol Chemical Structure

CAS No.: 523-92-2

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Voir tous les produits spécifiques à Isoform NF-κB :

Voir tous les produits spécifiques à Isoform TGF-β Receptor :

Voir tous les produits spécifiques à Isoform Akt :

Voir tous les produits spécifiques à Isoform Parasite :

In Vitro

Sequoyitol (1-10 μmol·L⁻¹; added 1 hour prior to the addition of high-glucose medium) protects rat mesangial cells from high-glucose-induced loss of viability, with the 10 μmol·L⁻¹ dose exerting a stronger protective effect^[1].
Sequoyitol (1-10 μmol·L⁻¹; added 1 hour prior to the addition of high-glucose medium) reduces excessive ROS production induced by high glucose in rat mesangial cells, with the 10 μmol·L⁻¹ dose exerting a more significant inhibitory effect on ROS levels^[1].
Sequoyitol (1-10 μmol·L⁻¹) reduces the level of high glucose-induced lipid peroxidation in rat mesangial cells, as evidenced by decreased MDA levels, with the inhibitory effect being stronger at the dose of 10 μmol·L⁻¹^[1].
Sequoyitol (1-10 μmol·L⁻¹) enhances the cellular antioxidant capacity of rat mesangial cells exposed to high glucose, with the 10 μmol·L⁻¹ dose exerting a more significant enhancing effect^[1].
Sequoyitol (100 μM; 12 h) directly enhances the insulin signaling pathway in HepG2 cells, including the phosphorylation of IRS1 and Akt, and reverses TNF-α-induced insulin resistance^[2].
Sequoyitol (100 μM; 16 h) directly suppresses DB-cAMP-stimulated gluconeogenesis in primary mouse hepatocytes in vitro in an insulin-independent manner, and exerts additive or synergistic effects to inhibit gluconeogenesis when combined with insulin^[2].
Sequoyitol (100 μM; 12 h) directly enhances the insulin signaling pathway in 3T3-L1 adipocytes, including the phosphorylation of IR, IRS1 and Akt, and reverses TNF-α-induced insulin resistance^[2].
Sequoyitol (5-10 mg/mL; 3-6 h) dose-dependently protects INS-1 pancreatic β-cells against STZ (HY-13753)- and H₂O₂-induced damage, and enhances the insulin signaling pathway in these cells^[2].
Sequoyitol (15 mM) induces single-amplitude action potentials in the lateral styloconic sensilla of fifth-instar Atrophaneura alcinous larvae, elicits a small number of small action potentials in the epipharyngeal sensilla, but causes no evoked responses in the medial styloconic sensilla^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:

human hepatoblastoma HepG2 cells
Concentration:

100 μM
Incubation Time:

12 h (pretreatment before 5 min insulin stimulation); 12 h (pretreatment with TNF-α before 5 min insulin stimulation)
Result:

Increased insulin-stimulated phosphorylation of IRS1 by 114% and Akt (pSer473) by 54% compared to control.
Increased insulin-stimulated phosphorylation of IR by 46%, IRS1 by 48%, and Akt (pSer473) by 61% in TNF-α-treated cells compared to TNF-α-only control.

Western Blot Analysis^[2]

Cell Line:

3T3-L1 mouse adipocytes
Concentration:

100 μM
Incubation Time:

12 h (pretreatment before 5 min insulin stimulation); 12 h (pretreatment with TNF-α before 5 min insulin stimulation)
Result:

Increased insulin-stimulated phosphorylation of IR by 31% and IRS1 by 73% compared to control.
Increased insulin-stimulated phosphorylation of IR by 53%, IRS1 by 69%, and Akt by 74% in TNF-α-treated cells compared to TNF-α-only control.

In Vivo

Sequoyitol (12.5-50.0 mg/kg; p.o.; daily; 6 weeks) ameliorates diabetic nephropathy in high-fat diet and streptozotocin-induced diabetic rats by reducing hyperglycemia, improving renal function, decreasing oxidative stress, and downregulating the expression of pro-fibrotic and pro-inflammatory mediators, with the highest dose producing the most significant effects^[1].
Sequoyitol (0.5 nmol/h; s.c.; continuous; 23 days) improves hyperglycemia, hyperinsulinemia, insulin resistance, and glucose intolerance in ob/ob mice by enhancing insulin signaling, including increasing Akt phosphorylation and reducing IRS1 Ser³⁰⁷ phosphorylation^[2].
Sequoyitol (40 mg/kg; p.o.; twice daily; up to 31 days) improves hyperglycemia and glucose intolerance in ob/ob mice of both sexes by enhancing insulin sensitivity without altering body weight or plasma insulin levels^[2].
Sequoyitol (70-100 mg·kg^-1·day^-1; p.o.; continuous; 31 days) reduces hyperglycemia, improves glucose intolerance, and increases plasma insulin levels in STZ-induced insulin-deficient C57BL/6 mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Sprague-Dawley (male, 6-8 weeks old, 180-220 g, induced by 4-week high-fat diet + intraperitoneal streptozotocin injection)^[1]
Dosage:

12.5 mg/kg; 25.0 mg/kg; 50.0 mg/kg
Administration:

p.o.; daily; 6 weeks
Result:

Significantly decreased fasting blood glucose levels compared to the diabetic model group, with 25.0 mg/kg and 50.0 mg/kg doses showing statistically significant reductions (# P < 0.05, ## P < 0.01).
Significantly increased plasma insulin levels compared to the diabetic model group, with 25.0 mg/kg and 50.0 mg/kg doses showing statistically significant elevations (# P < 0.05, ## P < 0.01).
Significantly decreased serum creatinine (SCr) and blood urea nitrogen (BUN) levels compared to the diabetic model group, with 50.0 mg/kg dose producing statistically significant reduction in SCr (## P < 0.01) and all doses producing statistically significant reductions in BUN (# P < 0.05, ## P < 0.01).
Improved renal histopathology, reducing glomerular hypertrophy, mesangial cell proliferation, and extracellular matrix accumulation compared to the diabetic model group.
Significantly decreased renal collagen IV mRNA and protein expression compared to the diabetic model group, with 50.0 mg/kg dose producing statistically significant reductions (## P < 0.01).
Significantly decreased renal p22phox and p47phox mRNA and protein expression compared to the diabetic model group, with 25.0 mg/kg and 50.0 mg/kg doses producing statistically significant reductions (## P < 0.01).
Significantly decreased renal malondialdehyde (MDA) levels and increased total antioxidative capacity (T-AOC) compared to the diabetic model group, with 50.0 mg/kg dose producing statistically significant changes (## P < 0.01).
Significantly decreased renal NF-κB mRNA and protein expression compared to the diabetic model group, with 50.0 mg/kg dose producing statistically significant reductions (## P < 0.01).
Significantly decreased renal TGF-β1 mRNA and protein expression compared to the diabetic model group, with 25.0 mg/kg and 50.0 mg/kg doses producing statistically significant reductions (## P < 0.01).

Animal Model:

ob/ob (male and female, 8-9 wk old, genetic obesity/insulin resistance model)^[2]
Dosage:

40 mg/kg
Administration:

p.o.; twice daily; up to 31 days
Result:

Did not alter body weight in males or females.
Reduced fasting blood glucose significantly in males (P=0.014) and reduced in females (P=0.08) compared to controls.
Lowered blood glucose levels significantly at multiple time points post-glucose injection during GTT in both sexes.
Maintained plasma insulin levels similar to control groups.
Lowered blood glucose levels significantly at 15, 30, and 60 minutes post-insulin injection during ITT in both males and females.

Animal Model:

C57BL/6 (male, 9 wk old, insulin deficiency model induced by streptozotocin injection)^[2]
Dosage:

70-100 mg·kg^-1·day^-1
Administration:

p.o.
Result:

Did not alter body weight.
Reduced random-fed blood glucose significantly at days 22 and 31 post-treatment, with a 26% reduction at day 31 compared to controls.
Increased plasma insulin levels by 155% compared to controls.
Lowered blood glucose levels significantly at 60 and 120 minutes post-glucose injection during GTT.
Reduced AUC during GTT significantly.

Chemical Information

CAS No. 523-92-2
Appearance Solid
Masse moléculaire 194.18
Formule C₇H₁₄O₆
Color White to off-white
SMILES

CO[C@@H]1[C@H]([C@@H]([C@H](O)[C@H](O)[C@H]1O)O)O
Synonyms

5-O-Methyl-myo-inositol
Structure Classification
- Others
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (1)

All

Sort by:

Journal Impact Factor

Insects

Electrophysiological and Morphological Characterization of Contact Chemosensilla in Adults and Larvae of the Butterfly, Atrophaneura alcinous. [Abstract]

2022 Sep 2;13(9):802. PMID: 36135503

Solvant et solubilité

In Vitro:

H₂O : 100 mg/mL (514.99 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

5.1499 mL

25.7493 mL

51.4986 mL

5 mM

1.0300 mL

5.1499 mL

10.2997 mL

10 mM

0.5150 mL

2.5749 mL

5.1499 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 100 mg/mL (514.99 mM); Clear solution; Need ultrasonic

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (320 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Li XW, et al. Sequoyitol ameliorates diabetic nephropathy in diabetic rats induced with a high-fat diet and a low dose of streptozotocin. Can J Physiol Pharmacol. 2014;92(5):405-417. [Content Brief]

[2]. Shen H, et al. Herbal constituent sequoyitol improves hyperglycemia and glucose intolerance by targeting hepatocytes, adipocytes, and β-cells. Am J Physiol Endocrinol Metab. 2012;302(8):E932-E940. [Content Brief]

[3]. Tsuchihara K, et al. Electrophysiological and Morphological Characterization of Contact Chemosensilla in Adults and Larvae of the Butterfly, Atrophaneura alcinous. Insects. 2022 Sep 2;13(9):802. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O	1 mM	5.1499 mL	25.7493 mL	51.4986 mL	128.7465 mL
	5 mM	1.0300 mL	5.1499 mL	10.2997 mL	25.7493 mL
	10 mM	0.5150 mL	2.5749 mL	5.1499 mL	12.8747 mL
	15 mM	0.3433 mL	1.7166 mL	3.4332 mL	8.5831 mL
	20 mM	0.2575 mL	1.2875 mL	2.5749 mL	6.4373 mL
	25 mM	0.2060 mL	1.0300 mL	2.0599 mL	5.1499 mL
	30 mM	0.1717 mL	0.8583 mL	1.7166 mL	4.2916 mL
	40 mM	0.1287 mL	0.6437 mL	1.2875 mL	3.2187 mL
	50 mM	0.1030 mL	0.5150 mL	1.0300 mL	2.5749 mL
	60 mM	0.0858 mL	0.4292 mL	0.8583 mL	2.1458 mL
	80 mM	0.0644 mL	0.3219 mL	0.6437 mL	1.6093 mL
	100 mM	0.0515 mL	0.2575 mL	0.5150 mL	1.2875 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Sequoyitol

1 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Sequoyitol

Antioxidant Compound Library

Differentiation Inducing Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Endocrinology Compound Library

Ferroptosis Compound Library

Medicine Food Homology Compound Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Antiparasitic Compound library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Food-Sourced Compound Library

Anti-Liver Cancer Compound Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Anti-Drug-Resistant Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Bioactive Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Lactylation Compound Library

Natural Product and Natural Product-Like Compound Library

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

TGF-beta/Smad Compound Library

Natural Product Library

Autophagy Compound Library

Anti-Aging Compound Library

Publications Citing Use of MedChemExpress (MCE) Sequoyitol

Voir tous les produits spécifiques à Isoform NF-κB

Voir tous les produits spécifiques à Isoform TGF-β Receptor

Voir tous les produits spécifiques à Isoform Akt

Voir tous les produits spécifiques à Isoform Parasite

Activité biologique

Chemical Information

Publications (1)